BG103548A - Vitronectine receptor antagonists - Google Patents

Vitronectine receptor antagonists

Info

Publication number
BG103548A
BG103548A BG103548A BG10354899A BG103548A BG 103548 A BG103548 A BG 103548A BG 103548 A BG103548 A BG 103548A BG 10354899 A BG10354899 A BG 10354899A BG 103548 A BG103548 A BG 103548A
Authority
BG
Bulgaria
Prior art keywords
vitronectine
receptor antagonists
antagonists
relates
integrin receptor
Prior art date
Application number
BG103548A
Other languages
Bulgarian (bg)
English (en)
Inventor
William Miller
William Bondinell
Thomas Ku
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG103548A publication Critical patent/BG103548A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
BG103548A 1997-01-08 1999-07-01 Vitronectine receptor antagonists BG103548A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08
PCT/US1998/000490 WO1998030542A1 (en) 1997-01-08 1998-01-08 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
BG103548A true BG103548A (en) 2000-11-30

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103548A BG103548A (en) 1997-01-08 1999-07-01 Vitronectine receptor antagonists

Country Status (30)

Country Link
US (2) US6069158A (es)
EP (1) EP0977735B1 (es)
JP (1) JP2001508067A (es)
KR (1) KR20000069941A (es)
CN (1) CN1249745A (es)
AP (1) AP9901597A0 (es)
AR (1) AR010873A1 (es)
AT (1) ATE235467T1 (es)
AU (1) AU729641B2 (es)
BG (1) BG103548A (es)
BR (1) BR9806852A (es)
CA (1) CA2276738A1 (es)
CO (1) CO4920232A1 (es)
DE (1) DE69812602T2 (es)
DZ (1) DZ2395A1 (es)
EA (1) EA199900630A1 (es)
ES (1) ES2196534T3 (es)
HU (1) HUP0001945A3 (es)
ID (1) ID23168A (es)
IL (1) IL130760A0 (es)
MA (1) MA26462A1 (es)
NO (1) NO993350L (es)
NZ (1) NZ336560A (es)
OA (1) OA11076A (es)
PE (1) PE44799A1 (es)
PL (1) PL334499A1 (es)
SK (1) SK92799A3 (es)
TR (1) TR199901575T2 (es)
WO (1) WO1998030542A1 (es)
ZA (1) ZA9896B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011626A1 (en) * 1997-09-04 1999-03-11 Smithkline Beecham Corporation Integrin receptor antagonists
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.
ATE542797T1 (de) 1998-04-09 2012-02-15 Meiji Seika Pharma Co Ltd Aminopiperidinderivate als integrin alpha v beta 3 antagonisten
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6943156B2 (en) 2000-10-24 2005-09-13 Merck & Co., Inc Dibenzoxazepine αv integrin receptor antagonist
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
CA2464472C (en) 2001-10-22 2014-01-07 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
AU2005229015C1 (en) * 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006128689A2 (de) 2005-05-31 2006-12-07 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
PL2101805T3 (pl) 2007-01-18 2013-04-30 Merck Patent Gmbh Ligandy integryn do stosowania w leczeniu nowotworów
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
KR20120104491A (ko) 2009-05-25 2012-09-21 메르크 파텐트 게엠베하 암 치료를 위한 실렌기티드의 연속 투여
WO2011011775A1 (en) 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
US4994463A (en) * 1987-12-14 1991-02-19 Kyowa Hakko Kogyo Co., Ltd. Tricyclic thromboxane A2 antagonists
EP0910563B1 (en) * 1995-06-29 2003-05-02 Smithkline Beecham Corporation Integrin receptor antagonists
WO1997024124A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP1000031A4 (en) * 1997-07-25 2001-08-16 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
IL130760A0 (en) 2001-01-28
AU729641B2 (en) 2001-02-08
EP0977735A4 (en) 2000-04-05
US6191304B1 (en) 2001-02-20
KR20000069941A (ko) 2000-11-25
EP0977735A1 (en) 2000-02-09
ID23168A (id) 2000-03-23
BR9806852A (pt) 2001-08-07
WO1998030542A1 (en) 1998-07-16
NO993350D0 (no) 1999-07-07
EA199900630A1 (ru) 2000-02-28
CO4920232A1 (es) 2000-05-29
CN1249745A (zh) 2000-04-05
JP2001508067A (ja) 2001-06-19
ZA9896B (en) 1998-10-14
ES2196534T3 (es) 2003-12-16
NO993350L (no) 1999-09-06
CA2276738A1 (en) 1998-07-16
DE69812602D1 (de) 2003-04-30
ATE235467T1 (de) 2003-04-15
US6069158A (en) 2000-05-30
HUP0001945A3 (en) 2001-12-28
AU5912798A (en) 1998-08-03
NZ336560A (en) 2000-11-24
PL334499A1 (en) 2000-02-28
TR199901575T2 (xx) 1999-11-22
EP0977735B1 (en) 2003-03-26
SK92799A3 (en) 1999-12-10
DZ2395A1 (fr) 2003-06-04
HUP0001945A2 (hu) 2000-10-28
AR010873A1 (es) 2000-07-12
DE69812602T2 (de) 2004-02-19
AP9901597A0 (en) 1999-09-30
OA11076A (en) 2003-03-13
PE44799A1 (es) 1999-06-10
MA26462A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
BG103548A (en) Vitronectine receptor antagonists
MX9805253A (es) Antagonistas del receptor de vitronectina.
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
DE69621225D1 (de) Tricyclische vasopressin antagonisten
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
EP0866705A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
BG104916A (en) Calcilytic compounds
ZA989784B (en) Novel cyclopentene derivatives useful as antagonists of the motilin receptor.
ZA9810685B (en) Thrombin receptor antagonists.
HK1032785A1 (en) Novel 3,6-hemiketals from the class of 9a-azalides
MY133390A (en) Azabicyclic 5ht1 receptor ligands
FI943941A0 (fi) CCK-reseptoriantagonisteina käyttökelpoiset bentsodiatsepiinijohdannaiset
FI960223A0 (fi) 1,5-bentsodiatsepiinijohdannaisia, jotka ovat käyttökelpoisia CCK- tai gastriiniantagonisteina
PL335100A1 (en) Oxazolynones as antagonists of 5ht2a receptor
EP0714295A4 (es)
HK1045684A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor.
PL338453A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor
AU1296899A (en) Phenyl-alkyl-imidazoles as h3 receptor antagonists
BG103649A (en) Method for the preparation of eprosartan
EP0681583A1 (en) TRICYCLIC HETEROCYCLIC COMPOUNDS AS 5-HT4 RECEPTOR ANTAGONISTS.
BG103650A (en) Method for the preparation of eprosartan
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM